Brickell is focused on the development of novel and differentiated therapies for the treatment of skin diseases.

Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated therapeutics for the treatment of skin diseases. Our current pipeline consists of new molecular entities targeting the treatment of the following indications: hyperhidrosis, atopic dermatitis, contact dermatitis and acne.

» READ MORE

Latest News

[July 8, 2015]

Brickell Announces Appointment of Industry Veterans Dr. Patricia Walker as President and CSO and Dr. Elizabeth Hussey as VP, Product Development

» READ ARTICLE


[April 1, 2015]

Brickell Signs Exclusive License and Development Agreement for its novel, topical soft-anticholigenric, BBI-4000, with Kaken Pharmaceutical Co., Ltd. in Japan.

» READ ARTICLE